Checkpoint Therapeutics, Inc.
CKPT
$4.04
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | -- | 41.00K | -- | 6.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | -- | 41.00K | -- | 6.00K |
| Cost of Revenue | 16.81M | 6.37M | 4.48M | 8.50M | 8.30M |
| Gross Profit | -16.81M | -6.37M | -4.44M | -8.50M | -8.29M |
| SG&A Expenses | 12.02M | 3.36M | 2.23M | 2.45M | 1.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.83M | 9.72M | 6.71M | 10.95M | 10.18M |
| Operating Income | -28.83M | -9.72M | -6.67M | -10.95M | -10.17M |
| Income Before Tax | -28.90M | -9.73M | -6.67M | -10.95M | -19.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.90M | -9.73M | -6.67M | -10.95M | -19.13M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.90M | -9.73M | -6.67M | -10.95M | -19.13M |
| EBIT | -28.83M | -9.72M | -6.67M | -10.95M | -10.17M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.63 | -0.23 | -0.18 | -0.33 | -0.69 |
| Normalized Basic EPS | -0.39 | -0.14 | -0.11 | -0.21 | -0.43 |
| EPS Diluted | -0.63 | -0.23 | -0.18 | -0.33 | -0.69 |
| Normalized Diluted EPS | -0.39 | -0.14 | -0.11 | -0.21 | -0.43 |
| Average Basic Shares Outstanding | 46.03M | 43.15M | 36.53M | 32.93M | 27.74M |
| Average Diluted Shares Outstanding | 46.03M | 43.15M | 36.53M | 32.93M | 27.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |